Jiang Qingyuan, Dai Lei, Cheng Lin, Chen Xiaolei, Li Yiming, Zhang Shuang, Su Xiaolan, Zhao Xia, Wei Yuquan, Deng Hongxin
State Key Laboratory of Biotherapy, West China Hospital, Sichuan, China.
J Obstet Gynaecol Res. 2013 Mar;39(3):701-9. doi: 10.1111/j.1447-0756.2012.02007.x. Epub 2012 Sep 25.
Signal transducer and activator of transcription 3 (STAT3) plays an important role in the tumor formation, prognosis and chemoresistance of ovarian cancer. Our goal was to investigate the effect of silencing STAT3 on ovarian cancer cell apoptosis, proliferation, angiogenesis and expression of key targets in vitro and in vivo.
The ovarian cancer cell lines A2780CP and A2780s were used. STAT3 was knocked down by the plasmid-based short hairpin RNA (shRNA) expression system. In vitro, a colony formation assay and Hoechst staining were used to examine cell proliferation and apoptosis. The expression level of STAT3 and apoptosis-related proteins were determined by Western blot. The A2780CP intraperitoneal model was used to evaluate the effect of shSTAT3 on tumor growth in mice. Proliferation, apoptosis, and angiogenesis in tumor tissues were measured by proliferating cell nuclear antigen, TUNEL and CD31 immunostaining, respectively.
Treatment with shSTAT3 resulted in apoptosis and inhibition of cell proliferation in vitro. Western blot analysis demonstrated that shSTAT3 induced the expression of cleaved caspase-3 and reduced the expression of survivin, Bcl-2 and vascular endothelial growth factor. In vivo, the tumor weight was reduced to 13.46% of 5% glucose by shSTAT3/lipoplexes (P < 0.01), accompanied with apoptosis induction (P < 0.01), proliferation inhibition (P < 0.01) and angiogenesis inhibition (P < 0.01).
We find that treatment with shSTAT3 inhibits tumor growth in vitro and in vivo by inducing apoptosis and inhibiting cell proliferation. This work should provide the scientific foundation for future investigation of shSTAT3 as a strategy for ovarian cancer gene therapy and the combination of gene therapy with chemotherapy.
信号转导与转录激活因子3(STAT3)在卵巢癌的肿瘤形成、预后及化疗耐药中发挥重要作用。我们的目标是在体外和体内研究沉默STAT3对卵巢癌细胞凋亡、增殖、血管生成及关键靶点表达的影响。
使用卵巢癌细胞系A2780CP和A2780s。通过基于质粒的短发夹RNA(shRNA)表达系统敲低STAT3。在体外,采用集落形成试验和Hoechst染色检测细胞增殖和凋亡。通过蛋白质免疫印迹法测定STAT3及凋亡相关蛋白的表达水平。利用A2780CP腹腔模型评估shSTAT3对小鼠肿瘤生长的影响。分别通过增殖细胞核抗原、TUNEL和CD31免疫染色检测肿瘤组织中的增殖、凋亡和血管生成情况。
shSTAT3处理导致体外细胞凋亡并抑制细胞增殖。蛋白质免疫印迹分析表明,shSTAT3诱导了裂解的半胱天冬酶-3的表达,降低了生存素、Bcl-2和血管内皮生长因子的表达。在体内,shSTAT3/脂质复合物使肿瘤重量降至5%葡萄糖处理组的13.46%(P<0.01),同时伴有凋亡诱导(P<0.01)、增殖抑制(P<0.01)和血管生成抑制(P<0.01)。
我们发现shSTAT3处理通过诱导凋亡和抑制细胞增殖在体外和体内抑制肿瘤生长。这项工作应为未来将shSTAT3作为卵巢癌基因治疗策略以及基因治疗与化疗联合应用的研究提供科学依据。